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complaints of diplopia, pain, edema and conjuctivitis on the right
eye. Steroid treatment was started and she was referred to our set-
ting because of total ophtalmoplegia on right eye. In addition to
right eye chemosis and edema, eye movements were restricted
in all directions with ﬁx-dilated pupilla. Orbital computer tomo-
graphy was interpreted as preorbital cellulitis. The patient was
internalized in the ophthalmology department with piperacilin-
tazobactam plus linezolid. After 5 days of treatment control MRI
revealed a fungal infection which inﬁltrated all of the compart-
ments of right eye, right cavernous sinüs plus occludes right
internal carotid artery. After this, the patient was transferred to
infectious diseases department with the diagnosis of mucormyco-
sis. Piperacillin-tazobactam was switched to meropenem (1gr q8h
i.v.). Also, amphotericin B deoxycholate 1mg/kg was started but
due to allergic reaction, it was changed with LAMB (5mg/kg/day).
Ethmoidal and sphenoidal sinüs biopsies revealed mucormycosis
in pathology.
Results: The surgical debridement was not found applicable
by surgical departments. The dose of LAMB was increased to
7mg/kg/day on the 10th day of LAMB. After six days posaconazole
(400mg/day q12h p.o.) was added due to no clinical improve-
ment.and worsening of the patient’s headache. Control Cranial
MRI showed progression. Therefore LAMB dose was increased to
10mg/kg/day and deferasirox was added (20mg/kg/day p.o.) at
the 15th day of treatment and contiunued for 14 days. After that,
clinical ﬁndings and control cranial MRI stable when compared
to previous MRI. On the 30th day of treatment LAMB dose was
decreased to 7mg/kg/day andmeropenemplus linezolid treatment
was stopped. The patient was discharged with posaconazole after
47 days of LAMB. Therewas no relapse on 3month follow-up of the
patient with posaconazole treatment which was given 2 months at
all.
Conclusion: Combination of antifungal antibiotics with
deferasirox may be successful in the salvae tehrapy of mucormy-
cosis.
http://dx.doi.org/10.1016/j.ijid.2014.03.1009
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Background: HIV-associated cryptococcal meningitis (CM) has
emerged as the commonest cause of adult meningitis in much
of Africa, and despite current anti-fungal treatments, acute CM-
relatedmortality in thedevelopingworld remainsbetween24-43%.
Novel adjuvant therapies aimed at reducing this high mortality are
urgently needed. Vitamin D is one such possible adjuvant treat-
ment. Vitamin D deﬁciency is associated with impaired immune
responses and increased susceptibility to a number of intra-
cellular pathogens in HIV-infected individuals. It is not known
whether such an association exists with Cryptococcus neofor-
mans.
Methods & Materials: Vitamin D levels were measured in 150
patients with cryptococcal meningitis (CM), and 150 HIV-infected
controls in Cape Town, South Africa, and associations between
vitamin D deﬁciency and CM examined. Vitamin D levels and
cryptococcal notiﬁcations were analysed for evidence of recipro-
cal seasonality. Associations between vitamin D levels and disease
severity, immune responses and microbiological clearance were
investigated in the patients with CM.
Results: Vitamin D deﬁciency (plasma 25(OH)D ≤50nmol/L)
was present in 74% of patients. Vitamin D deﬁciency was not asso-
ciated with CM (aOR 0.93, 95%CI 0.6-1.6, p=0.7), but was associated
with active TB. Vitamin D levels showed marked seasonality, but
no reciprocal seasonality was seen in CM notiﬁcations (ﬁgure 1).
No signiﬁcant associations were found between vitamin D levels
and fungal burden, cerebrospinal ﬂuid tumour necrosis factor-,
interferon-, interleukin-6, soluble-CD14 or neopterin levels (ﬁg-
ure 2). Rates of fungal clearance did not vary according to vitamin
D status.
Conclusion: Vitamin D deﬁciency does not predispose to the
development of CM, or lead to impaired immune responses or
microbiological clearance in HIV-infected patients with CM. These
data suggest that, in contrast to TB, vitamin D-dependent path-
ways are not of key importance in the host immune response to
cryptococcal infection.
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